De hecho, la va depende de l
CT-388 activates both GLP-1 and GIP receptors with a unique signaling profile: Signal-biased dual agonism: Potent cAMP signaling at both GLP-1R and GIPR Minimal to no beta-arrestin recruitment at either receptor Reduced receptor internalization and desensitization Potentially prolonged pharmacological activity GLP-1 receptor activation: Appetite suppression via hypothalamic and brainstem receptors Glucose-dependent insulin secretion Glucagon suppression Gastric emptying delay GIP receptor activation: Additional insulin sensitization Enhanced lipid metabolism Complementary appetite regulation Potential adipose tissue remodeling benefits The biased signaling mechanism is the key differentiator
F.BrownM.SanchezE.TattersallR
Deng, L., Yao, P., Li, L., Ji, F., Zhao, S., Xu, C., Lan, X., & Jiang, P
Lets take a look into the science behind this therapy and its transformative potential in treating age-related conditions
Lower doses may mean less weight loss
